Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Sambuchi

Neurology Amherst, NY Medical Doctor

NPI 1942203112 CMS profile 178956

3980 Sheridan Dr, Amherst, NY 14226

Open in the dashboard

General payments

$36,574

767 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$139,133

2 holdings reported · through program year 2025

Through program year 2025, Gregory Sambuchi of Amherst, NY is reported in the CMS Open Payments database as having received $36,574 across 767 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $139,133 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,244 53
2024 General $1,473 69
2023 General $2,221 104
2022 General $2,205 115
2021 General $1,952 115
2020 General $8,225 116
2019 General $19,254 195
2025 Ownership $116,798 1
2024 Ownership $22,334 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Sambuchi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gregory Sambuchi were reported at $1,244. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gregory Sambuchi Neurology median Middle half National median
2019 $19,254 $474 $118–$2,177 $163
2020 $8,225 $367 $82–$2,309 $114
2021 $1,952 $438 $104–$2,547 $132
2022 $2,205 $442 $103–$2,388 $149
2023 $2,221 $464 $119–$2,312 $160
2024 $1,473 $468 $119–$2,323 $164
2025 $1,244 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $17,584 45 payments
  2. Allergan Inc. $6,197 33 payments
  3. AbbVie, Inc. $1,446 67 payments
  4. Teva Pharmaceuticals USA, Inc. $1,421 70 payments
  5. UCB, Inc. $936 57 payments
  6. SK Life Science, Inc. $638 35 payments
  7. Amgen Inc. $605 23 payments
  8. Lundbeck LLC $604 22 payments
  9. Supernus Pharmaceuticals, Inc. $465 59 payments
  10. Amneal Pharmaceuticals LLC $407 25 payments
  11. Other $6,270 331 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,651 14 payments
  2. Food and Beverage $14,180 735 payments
  3. Travel and Lodging $5,013 13 payments
  4. Consulting Fee $2,650 1 payment
  5. Education $80 4 payments
Products named General payments · program years 2019–2025
  1. Fycompa $17,485 40 payments
  2. UBRELVY Neuroscience $6,003 24 payments
  3. Briviact $798 48 payments
  4. AIMOVIG $665 29 payments
  5. AJOVY $645 32 payments
  6. BOTOX $523 22 payments
  7. UBRELVY Neuroscience $472 24 payments
  8. AUSTEDO $445 29 payments
  9. TROKENDI XR $392 48 payments
  10. RYTARY $390 24 payments
  11. Other $9,327 481 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,641

Median for Psychiatry: 574

Drug cost

$498,784

Median for Psychiatry: $27,624

Branded share of claims

22.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex Pen (4 Pack) Interferon Beta-1a Brand 13 $124,659
Briviact Brivaracetam Brand 54 $79,392
Xcopri Cenobamate Brand 29 $46,653
Fycompa Perampanel Brand 39 $46,641
Aptiom Eslicarbazepine Acetate Brand 19 $45,449
Levetiracetam Generic 319 $13,930
Qulipta Atogepant Brand 11 $12,591
Rasagiline Mesylate Generic 30 $12,577
Rytary Carbidopa/Levodopa Brand 13 $12,484
Pregabalin Generic 211 $12,409

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$277,699

Of which drugs: $239,907

Medicare patients

233

Average age 68

Services billed

14,934

129 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 52%
Ischemic heart disease 34%
Diabetes 30%
Chronic kidney disease 30%
Depression 30%
COPD 24%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 19 32 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $170
$170 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $86
  • Lundbeck LLC $23
$109 — —
Gocovri
  • US WorldMeds, LLC $94
$94 — —
AJOVY
  • Teva Pharmaceuticals USA, Inc. $90
$90 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

767 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record